JAMA released more research today that further confirms the importance of CYP2D6 testing to determine tamoxifen efficacy. Full details at http://jama.ama-assn.org/cgi/content/short/302/13/1429. The conclusion: Recurrence Rates: 14.9% for extensive metabolizers 20.9% for intermediate metabolizers 29.0% for poor metabolizers This means that Extensive Metabolizers will get the same preventative outcome from tamoxifen as much more expensive aromatase [...]
Filed under: Personalized Medicine | Tagged: breast cancer, CYP, CYP2D6, Cytochrome, JAMA, Personalized Medicine, Pharmacogenetics, tamoxifen | Leave a Comment »
